China's Growing Control Over US Pharmaceutical Supply Chain

### Executive Summary The report highlights that China supplies 39.9% of U.S. imports of active pharmaceutical ingredients in 2024 and controls up to 99% of certain critical drug inputs, warning that this concentration—enabled in part by U.S. regulatory and clinical trial practices—creates a national security risk by potentially allowing pharmaceutical access to be used as geopolitical leverage.